watch tripl second pivot studi initi
updat model symdeko rais pt
vertex announc initi studi evalu tripl combin
tezacaftor ivacaftor cystic fibrosi cf
patient two copi mutat homozygot
second pivot program tripl studi heterozyg patient
minim function mutat het/min also underway vertex
expect addit tripl combin studi
initi well
updat therapeut model follow symdeko approv
us cf patient age homozyg
mutat patient least one mutat respons
tez/iva approv europ expect later year model chang
includ revis homozyg market includ market share
shift orkambi symdeko symdeko access new patient price
symdeko small adjust market penetr
rate net effect higher price target
tripl combin clinic trial get smaller shorter vertex
continu develop next-gen cf regimen tripl combin back
approv medicin particularli symdeko recal orkambi studi enrol
patient symdeko studi enrol patient
drug demonstr signific improv lung function week
symdeko backbon studi het/min patient enrol
patient four-week efficaci safeti data safeti data
collect requir regulatori submiss support nda
homozygot studi tripl enrol patient four-week efficaci
follow four-week run-in period tez/iva safeti data
het/min studi support nda could see data later year studi
combin tezacaftor plan decis
advanc pivot program base data two
studi demonstr percent predict forc expiratori volum
respect
symdeko launch underway us eu approv homozygot
patient least one mutat respons tez/iva expect
improv safeti profil orkambi patient may convert symdeko
symdeko reach homozyg patient inelig orkambi well
model updat re-evalu model includ share homozyg
market shift symdeko factor homozyg market elig
symdeko base orkambi inelig patient patient toler
orkambi new patient initi start symdeko vs orkambi combin
cf revenu slightli lower rang
recent announc compani guidanc estim orkambi
lower estim symdeko
increas
conclus symdeko backbon efficaci larg
segment cf popul vertex ideal posit bring tripl combin
cf market rapidli orkambi still grow symdeko launch
tripl come vertex continu build cf franchis time
could potenti reach cf popul
assum kalydeco label expand continu
assum price orkambi us europ row
assum expans orkambi children age
factor us launch symdeko homozygot patient one mutat respons tez/iva assum
commerci launch europ earli approv
symdeko assum price us eu row
assum symdeko elig patient popul initi homozyg market due new patient start initi
symdeko vs orkambi patient toler orkambi switch symdeko orkambi inelig patient
assum tripl combin launch heterozygot
royalti stream royalti pharma walk two tier year
increment decreas price pressur payer provid assum
kalydeco monotherapi gate conduct fibrosi rate cf misregul penetr patient receiv misregul penetr patient treat reduc chlorid conduct conduct popul treat kalydeco function market popul treat kalydeco total patient treat kalydeco y/i chang revenu orkambi surfac express fibrosi homozyg market homozyg treat homozyg market homozyg treat total homozyg treat y/i chang revenu homozygot tez/iva tripl combo heterozygot fibrosi heterozyg treat tripl heterozyg treat y/i chang tripl combo revenu sourc maxim research symdeko surfac express heterozygot fibrosi homozyg patient stop orkambi orkambi inelig homozyg age treat homozyg patient stop orkambi orkambi inelig new market homozyg treat symdeko- heterozyg treat treat symdeko- y/i chang revenu sourc maxim research exhibit europ market model
kalydeco monotherapi gate conduct fibrosi rate cf misregul channel penetr patient receiv misregul channel penetr patient treat reduc chlorid conduct conduct popul treat kalydeco function popul treat kalydeco total patient treat kalydeco gate y/i chang revenu orkambi surfac express fibrosi homozyg homozyg treat homozyg market homozyg treat total homozyg treat y/i chang revenu homozygot tez/iva tripl combo heterozygot fibrosi heterozyg heterozyg treat tripl heterozyg treat y/i chang tripl combo revenu heterozygot sourc maxim research symdeko surfac express heterozygot fibrosi homozyg stop orkambi orkambi inelig homozyg age treat symdeko- homozyg patient stop orkambi orkambi inelig new market homozyg treat symdeko- heterozyg treat treat y/i chang revenu sourc maxim research exhibit row market model
kalydeco monotherapi gate conduct australia canada fibrosi rate cf misregul channel penetr patient receiv misregul channel penetr patient treat reduc chlorid conduct cf conduct popul treat kalydeco function popul treat kalydeco total patient treat kalydeco y/i chang revenu orkambi surfac express australia canada fibrosi market homozyg treat homozyg market homozyg treat total homozyg treat y/i chang revenu homozygot tez/iva tripl combo heterozygot fibrosi heterozyg elgibl tez/iva tripl heterozyg treat y/i chang tripl combo revenu heterozygot sourc maxim research symdeko surfac express australia canada fibrosi homozyg stop orkambi orkambi inelig homozyg age treat symdeko- homozyg patient stop orkambi orkambi inelig new market homozyg treat symdeko- heterozyg treat treat y/i chang revenu sourc maxim research
thousand except per share data
interest incom net
loss discontinu oper
net incom attribut vertex
compani report maxim group estim
